Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H R Brunner

Showing results (511-520 of 564) with videos related to

Pageof 57
Sort By:
Archives Des Maladies Du Coeur Et Des Vaisseaux|June 1, 1988
[Arterial hypertension with hyperkalemia, tubular acidosis and normal renal function: Gordon syndrome and/or pseudohypoaldosteronism type II?]J L Ader, B Waeber, J M Suc, et al.
European Journal of Clinical Pharmacology|January 1, 1985
Haemodynamic and pharmacological effects of the converting enzyme inhibitor CGS 14824A in normal volunteersM D Schaller, J Nussberger, B Waeber, et al.
Kidney International|October 10, 1998
Circadian variations of renal sodium handling in patients with orthostatic hypotensionA Pechère-Bertschi, J Nussberger, J Biollaz, et al.
The American Journal of Medicine|January 1, 1975
The renin axis and vasoconstriction volume analysis for understanding and treating renovascular and renal hypertensionJ H Laragh, J E Sealey, F R Bühler, et al.
Hypertension (Dallas, Tex. : 1979)|June 1, 1986
Four-hour infusions of synthetic atrial natriuretic peptide in normal volunteersJ Biollaz, J Nussberger, M Porchet, et al.
Kidney International|October 1, 1987
Site of the action of a synthetic atrial natriuretic peptide evaluated in humansJ Biollaz, J Bidiville, J Diézi, et al.
Hypertension (Dallas, Tex. : 1979)|November 22, 1997
Effects of SR 49059, a new orally active and specific vasopressin V1 receptor antagonist, on vasopressin-induced vasoconstriction in humansR Weber, A Pechère-Bertschi, D Hayoz, et al.
British Journal of Clinical Pharmacology|May 1, 1981
Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjectsD B Brunner, G Desponds, J Biollaz, et al.
Clinical Pharmacology and Therapeutics|August 1, 1991
Effects of SCH 34826, an orally active inhibitor of atrial natriuretic peptide degradation, in healthy volunteersM Burnier, M Ganslmayer, F Perret, et al.
Fundamental & Clinical Pharmacology|January 1, 1988
Hemodynamic, renal, and endocrine effects of 4-h infusions of human atrial natriuretic peptide in normal volunteersJ Bidiville, G Waeber, M Porchet, et al.
Pageof 57

Showing results (511-520 of 564) with videos related to

Sort By:
Pageof 57
Archives Des Maladies Du Coeur Et Des Vaisseaux|June 1, 1988
[Arterial hypertension with hyperkalemia, tubular acidosis and normal renal function: Gordon syndrome and/or pseudohypoaldosteronism type II?]J L Ader, B Waeber, J M Suc, et al.
European Journal of Clinical Pharmacology|January 1, 1985
Haemodynamic and pharmacological effects of the converting enzyme inhibitor CGS 14824A in normal volunteersM D Schaller, J Nussberger, B Waeber, et al.
Kidney International|October 10, 1998
Circadian variations of renal sodium handling in patients with orthostatic hypotensionA Pechère-Bertschi, J Nussberger, J Biollaz, et al.
The American Journal of Medicine|January 1, 1975
The renin axis and vasoconstriction volume analysis for understanding and treating renovascular and renal hypertensionJ H Laragh, J E Sealey, F R Bühler, et al.
Hypertension (Dallas, Tex. : 1979)|June 1, 1986
Four-hour infusions of synthetic atrial natriuretic peptide in normal volunteersJ Biollaz, J Nussberger, M Porchet, et al.
Kidney International|October 1, 1987
Site of the action of a synthetic atrial natriuretic peptide evaluated in humansJ Biollaz, J Bidiville, J Diézi, et al.
Hypertension (Dallas, Tex. : 1979)|November 22, 1997
Effects of SR 49059, a new orally active and specific vasopressin V1 receptor antagonist, on vasopressin-induced vasoconstriction in humansR Weber, A Pechère-Bertschi, D Hayoz, et al.
British Journal of Clinical Pharmacology|May 1, 1981
Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjectsD B Brunner, G Desponds, J Biollaz, et al.
Clinical Pharmacology and Therapeutics|August 1, 1991
Effects of SCH 34826, an orally active inhibitor of atrial natriuretic peptide degradation, in healthy volunteersM Burnier, M Ganslmayer, F Perret, et al.
Fundamental & Clinical Pharmacology|January 1, 1988
Hemodynamic, renal, and endocrine effects of 4-h infusions of human atrial natriuretic peptide in normal volunteersJ Bidiville, G Waeber, M Porchet, et al.
Pageof 57